STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).